Maynard Um
-
-
-
-
-
-
-
EMA panel issues negative opinion on Omeros narsoplimab application
-
-
-
-
-
-
-
Omeros (OMER) Misses Q1 EPS by 12c
-
-
-
-
-
-
-
Omeros (OMER) halted on volatility, up 101%
-
-
-
-
-
-
-
Increasing unusual put option volume: CRML OMER FHN EXK FIVN
-
-
-
-
-
-
-
Omeros (OMER) FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell TA-TMA and Assigns Late September PDUFA Date
-
-
-
-
-
-
-
D. Boral Capital Starts Omeros Corp. (OMER) at Buy
-
-
-
-
-
-
-
Omeros (OMER) Misses Q2 EPS by 27c
435,001 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

